ストックスクリーナーアプリを入手
5.94
1.49%
-0.09
前日終値:
$6.03
開ける：
$6.03
24時間の取引高:
1.22M
Relative Volume:
0.76
時価総額：
$826.40M
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.5153
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
-1.00%
1か月 パフォーマンス:
+5.51%
6か月 パフォーマンス:
+9.39%
1年 パフォーマンス:
-18.29%
1日の値動き範囲:
$5.84
$6.10
1週間の範囲:
$5.755
$6.12
52週間の値動き範囲:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.94 | 838.92M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
What is HC Wainwright's Forecast for VIR FY2025 Earnings? - MarketBeat
Aug PreEarnings: Why Vir Biotechnology Inc stock remains resilientJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.4%Here's What Happened - MarketBeat
VIR: HC Wainwright & Co. Reiterates 'Buy' Rating with $15 Price Target | VIR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Risk Report & Stepwise Trade Signal Implementation - Улправда
EV Market: Can Vir Biotechnology Inc. stock resist market sell offsEarnings Recap Summary & Precise Buy Zone Tips - Улправда
Aug Swings: Will Vir Biotechnology Inc stock benefit from M A activityOptions Play & Weekly Sector Rotation Insights - moha.gov.vn
Why analysts remain bullish on Vir Biotechnology Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Is Vir Biotechnology Inc. stock a buy for dividend growthJuly 2025 Highlights & Weekly Breakout Stock Alerts - Улправда
Momentum Shift: Can Vir Biotechnology Inc. stock beat market expectations this quarterJuly 2025 Highlights & Weekly Stock Breakout Alerts - Улправда
Can Vir Biotechnology Inc. stock sustain revenue growthQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - DonanımHaber
Will Vir Biotechnology Inc. stock outperform value stocks2025 Short Interest & Weekly High Return Stock Opportunities - DonanımHaber
Published on: 2025-12-19 13:20:41 - Улправда
How Vir Biotechnology Inc. stock performs after earnings2025 Trading Volume Trends & Technical Entry and Exit Tips - Улправда
Will Vir Biotechnology Inc. stock recover faster than market2025 Sector Review & Reliable Breakout Forecasts - Улправда
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Legal Desire Media and Insights
Vir Biotechnology stock gains on Norgine partnership for Hepatitis Delta program - Investing.com Canada
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology | Corporate - EQS News
Norgine Pharmaceuticals Limited - AD HOC NEWS
EQS-News: Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnologyboerse.de - boerse.de
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire
Vir Biotechnology Licenses CHD Combination Therapy to Norgine for Europe, Australia, New Zealand - marketscreener.com
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - Seeking Alpha
Vir Biotechnology Secures Licensing Deal with Norgine - TipRanks
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal - Investing.com Canada
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Secures Exclusive Licensing Deal with No - GuruFocus
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology stock rises after licensing hepatitis delta treatment By Investing.com - Investing.com Canada
Vir Biotechnology grants Norgine exclusive commercial license to chronic hepatitis delta treatment candidate - marketscreener.com
Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate - TradingView — Track All Markets
Vir Biotechnology signs agreement with Norgine for hepatitis Delta treatment - Traders Union
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment - StreetInsider
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
Vir Biotechnology secures licensing deal with Norgine - MSN
Vir Biotechnology Earnings Notes - Trefis
12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC - MarketBeat
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal - Investing.com
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Nasdaq Index Fund Health Drive - Kalkine Media
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
Vir Biotechnology Inc (VIR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10% Owner |
Dec 01 '25 |
Sale |
5.98 |
191,854 |
1,147,786 |
13,728,924 |
| SATO VICKI L | Director |
Dec 01 '25 |
Sale |
6.00 |
22,000 |
132,070 |
1,188,391 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 26 '25 |
Sale |
6.39 |
127,938 |
817,652 |
13,982,271 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 28 '25 |
Sale |
6.44 |
61,493 |
396,015 |
13,920,778 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 25 '25 |
Sale |
6.38 |
235,971 |
1,505,495 |
14,110,209 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 24 '25 |
Sale |
6.15 |
227,803 |
1,400,783 |
14,346,180 |
0.57%
大文字化:
|
ボリューム (24 時間):